CN103724337A - 一类含萘环和噻唑啉酮结构的吡唑啉类衍生物及其制法 - Google Patents
一类含萘环和噻唑啉酮结构的吡唑啉类衍生物及其制法 Download PDFInfo
- Publication number
- CN103724337A CN103724337A CN201210390426.3A CN201210390426A CN103724337A CN 103724337 A CN103724337 A CN 103724337A CN 201210390426 A CN201210390426 A CN 201210390426A CN 103724337 A CN103724337 A CN 103724337A
- Authority
- CN
- China
- Prior art keywords
- reaction
- recrystallization
- temperature
- naphthaldehyde
- organic solvent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 33
- 150000003219 pyrazolines Chemical class 0.000 title claims abstract description 16
- 125000001624 naphthyl group Chemical group 0.000 title abstract description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 63
- 238000006243 chemical reaction Methods 0.000 claims description 38
- KWOLFJPFCHCOCG-UHFFFAOYSA-N Acetophenone Chemical compound CC(=O)C1=CC=CC=C1 KWOLFJPFCHCOCG-UHFFFAOYSA-N 0.000 claims description 35
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 30
- 238000001953 recrystallisation Methods 0.000 claims description 30
- 239000000047 product Substances 0.000 claims description 23
- 239000003960 organic solvent Substances 0.000 claims description 18
- 150000001875 compounds Chemical class 0.000 claims description 16
- 239000007787 solid Substances 0.000 claims description 15
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 12
- 238000001816 cooling Methods 0.000 claims description 12
- 239000011259 mixed solution Substances 0.000 claims description 12
- 238000000967 suction filtration Methods 0.000 claims description 12
- 238000005406 washing Methods 0.000 claims description 12
- SQAINHDHICKHLX-UHFFFAOYSA-N 1-naphthaldehyde Chemical compound C1=CC=C2C(C=O)=CC=CC2=C1 SQAINHDHICKHLX-UHFFFAOYSA-N 0.000 claims description 11
- 150000002790 naphthalenes Chemical class 0.000 claims description 11
- PJKVFARRVXDXAD-UHFFFAOYSA-N 2-naphthaldehyde Chemical compound C1=CC=CC2=CC(C=O)=CC=C21 PJKVFARRVXDXAD-UHFFFAOYSA-N 0.000 claims description 10
- 150000004002 naphthaldehydes Chemical class 0.000 claims description 9
- 238000003756 stirring Methods 0.000 claims description 8
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims description 7
- PQJJJMRNHATNKG-UHFFFAOYSA-N ethyl bromoacetate Chemical compound CCOC(=O)CBr PQJJJMRNHATNKG-UHFFFAOYSA-N 0.000 claims description 7
- BRWIZMBXBAOCCF-UHFFFAOYSA-N hydrazinecarbothioamide Chemical compound NNC(N)=S BRWIZMBXBAOCCF-UHFFFAOYSA-N 0.000 claims description 7
- 239000001632 sodium acetate Substances 0.000 claims description 7
- 235000017281 sodium acetate Nutrition 0.000 claims description 7
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical group CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 6
- 239000006227 byproduct Substances 0.000 claims description 6
- 238000010438 heat treatment Methods 0.000 claims description 6
- 238000005457 optimization Methods 0.000 claims description 6
- 239000012153 distilled water Substances 0.000 claims description 4
- UFWIBTONFRDIAS-UHFFFAOYSA-N naphthalene-acid Natural products C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 claims description 4
- 239000000243 solution Substances 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- 150000008062 acetophenones Chemical class 0.000 claims description 3
- 238000000034 method Methods 0.000 claims description 3
- 239000013078 crystal Substances 0.000 description 14
- 239000000843 powder Substances 0.000 description 13
- 229960004756 ethanol Drugs 0.000 description 12
- 238000001514 detection method Methods 0.000 description 6
- GJGROPRLXDXIAN-UHFFFAOYSA-N 1,3-thiazol-4-one Chemical compound O=C1CSC=N1 GJGROPRLXDXIAN-UHFFFAOYSA-N 0.000 description 4
- GNKZMNRKLCTJAY-UHFFFAOYSA-N 4'-Methylacetophenone Chemical compound CC(=O)C1=CC=C(C)C=C1 GNKZMNRKLCTJAY-UHFFFAOYSA-N 0.000 description 4
- NTPLXRHDUXRPNE-UHFFFAOYSA-N 4-methoxyacetophenone Chemical compound COC1=CC=C(C(C)=O)C=C1 NTPLXRHDUXRPNE-UHFFFAOYSA-N 0.000 description 4
- -1 Lyeopene Chemical compound 0.000 description 3
- 229960000935 dehydrated alcohol Drugs 0.000 description 3
- 230000002147 killing effect Effects 0.000 description 3
- 125000002755 pyrazolinyl group Chemical group 0.000 description 3
- 0 *C1N(C(N)=S)N=C(*)C1 Chemical compound *C1N(C(N)=S)N=C(*)C1 0.000 description 2
- WBPAOUHWPONFEQ-UHFFFAOYSA-N 1-(3,4-dichlorophenyl)ethanone Chemical compound CC(=O)C1=CC=C(Cl)C(Cl)=C1 WBPAOUHWPONFEQ-UHFFFAOYSA-N 0.000 description 2
- WYECURVXVYPVAT-UHFFFAOYSA-N 1-(4-bromophenyl)ethanone Chemical compound CC(=O)C1=CC=C(Br)C=C1 WYECURVXVYPVAT-UHFFFAOYSA-N 0.000 description 2
- YOMBUJAFGMOIGS-UHFFFAOYSA-N 2-fluoro-1-phenylethanone Chemical compound FCC(=O)C1=CC=CC=C1 YOMBUJAFGMOIGS-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 244000144972 livestock Species 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- GVOISEJVFFIGQE-YCZSINBZSA-N n-[(1r,2s,5r)-5-[methyl(propan-2-yl)amino]-2-[(3s)-2-oxo-3-[[6-(trifluoromethyl)quinazolin-4-yl]amino]pyrrolidin-1-yl]cyclohexyl]acetamide Chemical compound CC(=O)N[C@@H]1C[C@H](N(C)C(C)C)CC[C@@H]1N1C(=O)[C@@H](NC=2C3=CC(=CC=C3N=CN=2)C(F)(F)F)CC1 GVOISEJVFFIGQE-YCZSINBZSA-N 0.000 description 2
- HBENZIXOGRCSQN-VQWWACLZSA-N (1S,2S,6R,14R,15R,16R)-5-(cyclopropylmethyl)-16-[(2S)-2-hydroxy-3,3-dimethylpentan-2-yl]-15-methoxy-13-oxa-5-azahexacyclo[13.2.2.12,8.01,6.02,14.012,20]icosa-8(20),9,11-trien-11-ol Chemical compound N1([C@@H]2CC=3C4=C(C(=CC=3)O)O[C@H]3[C@@]5(OC)CC[C@@]2([C@@]43CC1)C[C@@H]5[C@](C)(O)C(C)(C)CC)CC1CC1 HBENZIXOGRCSQN-VQWWACLZSA-N 0.000 description 1
- FANCTJAFZSYTIS-IQUVVAJASA-N (1r,3s,5z)-5-[(2e)-2-[(1r,3as,7ar)-7a-methyl-1-[(2r)-4-(phenylsulfonimidoyl)butan-2-yl]-2,3,3a,5,6,7-hexahydro-1h-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol Chemical compound C([C@@H](C)[C@@H]1[C@]2(CCCC(/[C@@H]2CC1)=C\C=C\1C([C@@H](O)C[C@H](O)C/1)=C)C)CS(=N)(=O)C1=CC=CC=C1 FANCTJAFZSYTIS-IQUVVAJASA-N 0.000 description 1
- SHAHPWSYJFYMRX-GDLCADMTSA-N (2S)-2-(4-{[(1R,2S)-2-hydroxycyclopentyl]methyl}phenyl)propanoic acid Chemical compound C1=CC([C@@H](C(O)=O)C)=CC=C1C[C@@H]1[C@@H](O)CCC1 SHAHPWSYJFYMRX-GDLCADMTSA-N 0.000 description 1
- KAFZOLYKKCWUBI-HPMAGDRPSA-N (2s)-2-[[(2s)-2-[[(2s)-1-[(2s)-3-amino-2-[[(2s)-2-[[(2s)-2-(3-cyclohexylpropanoylamino)-4-methylpentanoyl]amino]-5-methylhexanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]butanediamide Chemical compound N([C@@H](CC(C)C)C(=O)N[C@@H](CCC(C)C)C(=O)N[C@@H](CN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC(N)=O)C(N)=O)C(=O)CCC1CCCCC1 KAFZOLYKKCWUBI-HPMAGDRPSA-N 0.000 description 1
- VUDZSIYXZUYWSC-DBRKOABJSA-N (4r)-1-[(2r,4r,5r)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-4-hydroxy-1,3-diazinan-2-one Chemical compound FC1(F)[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)N[C@H](O)CC1 VUDZSIYXZUYWSC-DBRKOABJSA-N 0.000 description 1
- VIMMECPCYZXUCI-MIMFYIINSA-N (4s,6r)-6-[(1e)-4,4-bis(4-fluorophenyl)-3-(1-methyltetrazol-5-yl)buta-1,3-dienyl]-4-hydroxyoxan-2-one Chemical compound CN1N=NN=C1C(\C=C\[C@@H]1OC(=O)C[C@@H](O)C1)=C(C=1C=CC(F)=CC=1)C1=CC=C(F)C=C1 VIMMECPCYZXUCI-MIMFYIINSA-N 0.000 description 1
- IGVKWAAPMVVTFX-BUHFOSPRSA-N (e)-octadec-5-en-7,9-diynoic acid Chemical compound CCCCCCCCC#CC#C\C=C\CCCC(O)=O IGVKWAAPMVVTFX-BUHFOSPRSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- ZDKAJODZVYYAAL-UHFFFAOYSA-N 2-(3-naphthalen-1-yl-5-phenyl-3,4-dihydropyrazol-2-yl)-1,3-thiazol-4-one Chemical compound O=C1CSC(N2C(CC(=N2)C=2C=CC=CC=2)C=2C3=CC=CC=C3C=CC=2)=N1 ZDKAJODZVYYAAL-UHFFFAOYSA-N 0.000 description 1
- BVQPQYATPTWBFE-UHFFFAOYSA-N 2-(3-naphthalen-2-yl-5-phenyl-3,4-dihydropyrazol-2-yl)-1,3-thiazol-4-one Chemical compound O=C1CSC(N2C(CC(=N2)C=2C=CC=CC=2)C=2C=C3C=CC=CC3=CC=2)=N1 BVQPQYATPTWBFE-UHFFFAOYSA-N 0.000 description 1
- KVXIHMAQGVNYMX-UHFFFAOYSA-N 2-[5-(4-bromophenyl)-3-naphthalen-1-yl-3,4-dihydropyrazol-2-yl]-1,3-thiazol-4-one Chemical compound C1=CC(Br)=CC=C1C1=NN(C=2SCC(=O)N=2)C(C=2C3=CC=CC=C3C=CC=2)C1 KVXIHMAQGVNYMX-UHFFFAOYSA-N 0.000 description 1
- ZTJMSEMWBCKHCF-UHFFFAOYSA-N 2-[5-(4-bromophenyl)-3-naphthalen-2-yl-3,4-dihydropyrazol-2-yl]-1,3-thiazol-4-one Chemical compound C1=CC(Br)=CC=C1C1=NN(C=2SCC(=O)N=2)C(C=2C=C3C=CC=CC3=CC=2)C1 ZTJMSEMWBCKHCF-UHFFFAOYSA-N 0.000 description 1
- UZTIDIWVXCTNLX-UHFFFAOYSA-N 2-[5-(4-fluorophenyl)-3-naphthalen-1-yl-3,4-dihydropyrazol-2-yl]-1,3-thiazol-4-one Chemical compound C1=CC(F)=CC=C1C1=NN(C=2SCC(=O)N=2)C(C=2C3=CC=CC=C3C=CC=2)C1 UZTIDIWVXCTNLX-UHFFFAOYSA-N 0.000 description 1
- UBNXOSPQEJVHFK-UHFFFAOYSA-N 2-[5-(4-fluorophenyl)-3-naphthalen-2-yl-3,4-dihydropyrazol-2-yl]-1,3-thiazol-4-one Chemical compound C1=CC(F)=CC=C1C1=NN(C=2SCC(=O)N=2)C(C=2C=C3C=CC=CC3=CC=2)C1 UBNXOSPQEJVHFK-UHFFFAOYSA-N 0.000 description 1
- TYVIXJVZGLOQNA-UHFFFAOYSA-N 2-[5-(4-methylphenyl)-3-naphthalen-1-yl-3,4-dihydropyrazol-2-yl]-1,3-thiazol-4-one Chemical compound C1=CC(C)=CC=C1C1=NN(C=2SCC(=O)N=2)C(C=2C3=CC=CC=C3C=CC=2)C1 TYVIXJVZGLOQNA-UHFFFAOYSA-N 0.000 description 1
- LJRCLIXPPJBOKX-UHFFFAOYSA-N 2-[5-(4-methylphenyl)-3-naphthalen-2-yl-3,4-dihydropyrazol-2-yl]-1,3-thiazol-4-one Chemical compound C1=CC(C)=CC=C1C1=NN(C=2SCC(=O)N=2)C(C=2C=C3C=CC=CC3=CC=2)C1 LJRCLIXPPJBOKX-UHFFFAOYSA-N 0.000 description 1
- JOFDSYLCZIHGGO-UHFFFAOYSA-N 4-[(4-cyclohexylphenyl)methyl-[2-[[5-(dimethylamino)naphthalen-1-yl]sulfonyl-methylamino]acetyl]amino]-2-hydroxybenzoic acid Chemical compound C1=CC=C2C(N(C)C)=CC=CC2=C1S(=O)(=O)N(C)CC(=O)N(C=1C=C(O)C(C(O)=O)=CC=1)CC(C=C1)=CC=C1C1CCCCC1 JOFDSYLCZIHGGO-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- PANKHBYNKQNAHN-JTBLXSOISA-N Crocetin Natural products OC(=O)C(\C)=C/C=C/C(/C)=C\C=C\C=C(\C)/C=C/C=C(/C)C(O)=O PANKHBYNKQNAHN-JTBLXSOISA-N 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- TZYWCYJVHRLUCT-VABKMULXSA-N N-benzyloxycarbonyl-L-leucyl-L-leucyl-L-leucinal Chemical compound CC(C)C[C@@H](C=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)OCC1=CC=CC=C1 TZYWCYJVHRLUCT-VABKMULXSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- UIQDOXQEBKINNM-UHFFFAOYSA-N O=C1N=C(N(C(C2)c3cc4ccccc4cc3)N=C2c(cc2)ccc2Cl)SC1 Chemical compound O=C1N=C(N(C(C2)c3cc4ccccc4cc3)N=C2c(cc2)ccc2Cl)SC1 UIQDOXQEBKINNM-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- YLEIFZAVNWDOBM-ZTNXSLBXSA-N ac1l9hc7 Chemical compound C([C@H]12)C[C@@H](C([C@@H](O)CC3)(C)C)[C@@]43C[C@@]14CC[C@@]1(C)[C@@]2(C)C[C@@H]2O[C@]3(O)[C@H](O)C(C)(C)O[C@@H]3[C@@H](C)[C@H]12 YLEIFZAVNWDOBM-ZTNXSLBXSA-N 0.000 description 1
- 239000003905 agrochemical Substances 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- SRVFFFJZQVENJC-IHRRRGAJSA-N aloxistatin Chemical compound CCOC(=O)[C@H]1O[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCCC(C)C SRVFFFJZQVENJC-IHRRRGAJSA-N 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- OSVHLUXLWQLPIY-KBAYOESNSA-N butyl 2-[(6aR,9R,10aR)-1-hydroxy-9-(hydroxymethyl)-6,6-dimethyl-6a,7,8,9,10,10a-hexahydrobenzo[c]chromen-3-yl]-2-methylpropanoate Chemical compound C(CCC)OC(C(C)(C)C1=CC(=C2[C@H]3[C@H](C(OC2=C1)(C)C)CC[C@H](C3)CO)O)=O OSVHLUXLWQLPIY-KBAYOESNSA-N 0.000 description 1
- PANKHBYNKQNAHN-JUMCEFIXSA-N carotenoid dicarboxylic acid Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C(=O)O)C=CC=C(/C)C(=O)O PANKHBYNKQNAHN-JUMCEFIXSA-N 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- PANKHBYNKQNAHN-MQQNZMFNSA-N crocetin Chemical compound OC(=O)C(/C)=C/C=C/C(/C)=C/C=C/C=C(\C)/C=C/C=C(\C)C(O)=O PANKHBYNKQNAHN-MQQNZMFNSA-N 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- RWWYLEGWBNMMLJ-YSOARWBDSA-N remdesivir Chemical compound NC1=NC=NN2C1=CC=C2[C@]1([C@@H]([C@@H]([C@H](O1)CO[P@](=O)(OC1=CC=CC=C1)N[C@H](C(=O)OCC(CC)CC)C)O)O)C#N RWWYLEGWBNMMLJ-YSOARWBDSA-N 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Abstract
Description
技术领域
本发明涉及一类含萘环和噻唑啉酮结构的吡唑啉类衍生物及其制备方法。
背景技术
噻唑啉酮类衍生物及其同分异构体被广泛应用于农药和医药方面,由于能不可逆的抑制微生物的生长,对常见的细菌、真菌和藻类等具有很强的抑制和杀灭作用,杀生效率高,降解性好,具有不产生残留、操作安全、配伍性好、稳定性强、使用成本低等特点,近期研究表面,此类衍生物对糖尿病和肿瘤也有一定的效用,其前景引人瞩目。
萘环结构也具有一定的杀生能力,其在合成医药中间体方面的应用不可忽视,其空间结构与藏红花酸、番茄红素、维生素A等具有一定相似性,成为近期研究中分子修饰的热点。
吡唑啉结构作为常用的官能团,拥有广泛的药理特性:解热镇痛,抗风湿。被认为具有抗炎和抗癌活性,同时也是重要的支持结构。
基于以上研究我们合成了一系列含萘环和噻唑啉酮结构的吡唑啉类衍生物,由于其独特的骨架结构以及合理的修饰,对于寻找具有更高或更广谱的生物活性、更高的选择性、更低的毒性、更长或更短的残效性的药物前体具有十分重要的意义,同时,对于开展合理的分子设计和从天然生物活性物质中筛选新型活性分子,也有着理论指导价值。
发明内容
本发明的目的在于提供一类新型的含萘环和噻唑啉酮结构的吡唑啉类衍生物及其制备方法。
本发明的技术方案如下:
一类含萘环和噻唑啉酮结构的吡唑啉类衍生物,其特征是它有如下通式:
结构式中R1为如下基团之一:
R2为如下基团之一:
一种制备上述含萘环和噻唑啉酮结构的吡唑啉类衍生物的方法,它包括如下步骤:
步骤1.将取代基苯乙酮,萘甲醛溶于有机溶剂中,磁搅拌使混合均匀,缓慢滴入NaOH溶液,磁搅拌,常温反应2h(TLC检测反应进行程度),产物以固体析出。反应结束后抽滤,并以大量的蒸馏水和冷乙醇洗涤固体,干燥,重结晶;
步骤2.将步骤1中所得产物与硫代氨基脲,以有机溶剂加热溶解,加热搅拌反应10h(TLC检测)。反应结束后,冷却,产物以固体形态析出,抽滤并以冷乙醇洗涤,干燥,重结晶;
步骤3.将步骤2中所得产物、溴乙酸乙酯与乙酸钠,以有机溶剂加热溶解,加热搅拌反应5h(TLC检测)。反应结束后,冷却,产物以固体形态析出,抽滤并以冷乙醇洗涤,重结晶得到目标化合物。
步骤1中所述的取代苯乙酮与萘甲醛的投料摩尔比为1∶(1-1.1),最优投料摩尔比为1∶1.05,所述的有机溶剂为乙醇,所述的磁搅拌时间为10min,所述的萘甲醛可以分别为1-萘甲醛或2-萘甲醛,所述pH值为8-10,最优pH值为9.1,所述的反应温度为常温,所述的重结晶条件为采用体积比为10∶1的乙醇与丙酮混合液重结晶;
步骤2中所述的第一步产物与硫代氨基脲的投料摩尔比为1∶(1-1.1),最优投料摩尔比为1∶1.05,所述的有机溶剂为异丙醇或乙醇,所述的反应温度为75-85℃,最优反应温度为80℃,所述的冷却温度为5℃以下,所述的重结晶条件为采用体积比为10∶1的乙醇与丙酮混合液重结晶;
步骤3中所述的第二步产物与溴乙酸乙酯、乙酸钠的投料摩尔比为1∶(1-1.1)∶(1.0-1.8),最优投料摩尔比为1∶1∶1.5,所述的有机溶剂为异丙醇或乙醇,所述的反应温度为75-85℃,最优反应温度为80℃,所述的冷却温度为5℃以下,所述的重结晶条件为采用体积比为10∶1的乙醇与丙酮混合液重结晶。
本发明的优点是:本发明所述的衍生物具有独特的噻唑啉酮结构,被报道是许多酶抑制剂的特征结构,易被靶标识别和结合;首次将噻唑啉酮结构与萘环和吡唑啉结构进行合理拼接,强化了药效基团的比例,增大了运输和透膜的可能。
具体实施方式
通过以下实施例进一步详细说明本发明,但应注意本发明的范围并不受这些实施例的任何限制。
实施例一:2-(5-(萘-1-基)-3-苯基-4,5-二氢-1H-吡唑-1-基)噻唑-4(5H)-酮(化合物1a)的制备
取5.0mmol苯乙酮和5.25mmol 1-萘甲醛加入到50ml的圆底烧瓶中,加入20ml无水乙醇,磁搅拌10min使混合均匀,缓慢滴入40%NaOH溶液10ml(pH值为9.1),磁搅拌,常温反应2h(TLC检测反应进行程度),产物以固体析出,抽滤,并以大量的蒸馏水洗涤固体物,用冷乙醇洗涤3次(每次3ml),干燥,产物用乙醇与丙酮混合液(体积比乙醇∶丙酮=10∶1)重结晶;在50ml烧瓶中加入2.0mmol上述产物,2.1mmol硫代氨基脲,以20ml无水乙醇加热至80℃溶解,80℃回流反应10h(TLC检测)。反应结束后,冷却至5℃以下,产物以固体形态析出,抽滤并以冷乙醇洗涤3次(每次3ml),干燥,产物用乙醇与丙酮混合液(体积比乙醇∶丙酮=10∶1)重结晶;在25ml烧瓶中加入1.0mmol上述产物,1.0mmol溴乙酸乙酯,1.5mmol乙酸钠,以10ml无水乙醇加热至80℃溶解,80℃回流反应5h(TLC检测)。反应结束后,冷却至5℃以下,产物以固体形态析出,抽滤并以冷乙醇洗涤3次(每次1ml),干燥,产物用乙醇与丙酮混合液(体积比乙醇∶丙酮=10∶1)重结晶得到纯净的化合物1a(白色晶体)。White crystal,Yield 73%,mp:231-233℃.1H NMR(CDCl3,300MHz)δ:3.02-3.10(dd,J1=18.0Hz,J2=3.6Hz,1H),3.91(s,2H),4.09-4.18(dd,J1=18.0Hz,J2=11.4Hz,1H),6.64-6.69(dd,J1=11.4Hz,J2=3.3Hz,1H),7.01-7.03(d,J=6.9Hz,1H),7.39-7.44(m,4H),7.54-7.63(m,2H),7.80-7.87(m,3H),7.95-7.98(d,J=8.1Hz,1H),8.15-8.18(d,J=8.1Hz,1H).MS(ESI):372.11(C22H18N3OS,[M+H]+).Anal.Calcd for C22H17N3OS:C,71.14;H,4.61;N,11.31;O,4.31;S,8.63.Found:C,71.01;H,4.60;N,11.29.
实施例二:2-(3-(4-氟苯基)-5-(萘-1-基)-4,5-二氢-1H-吡唑-1-基)噻唑-4(5H)-酮(化合物2a)的制备
制备方法同实施例一。以对氟苯乙酮代替实例一中的苯乙酮,得到白色晶体状目标化合物。White crystal,Yield 68%,mp:238-240℃.1H NMR(CDCl3,300MHz)δ:3.12-3.19(dd,J1=17.4Hz,J2=3.7Hz,1H),3.90(s,2H),3.96-4.05(dd,J1=17.4Hz,J2=11.4Hz,1H),6.35(m,1H),6.79-6.84(dd,J1=11.1Hz,J2=3.3Hz,1H),7.06-7.12(t,J=8.7Hz,1H),7.21-7.28(m,1H),7.40-7.46(t,J=7.5Hz,1H),7.51-7.62(m,2H),7.67-7.72(dd,J1=9.0Hz,J2=5.4Hz,2H),7.77-7.80(d,J=8.4Hz,1H),7.90-7.93(d,J=8.4Hz,1H),8.01-8.04(d,J=8.1Hz,1H).MS(ESI):390.10(C22H17FN3OS,[M+H]+).Anal.Calcd for C22H16FN3OS:C,67.85;H,4.14;F,4.88;N,10.79;O,4.11;S,8.23.Found:C,68.41;H,4.13;N,10.78.
实施例三:2-(3-(4-氯苯基)-5-(萘-1-基)-4,5-二氢-1H-吡唑-1-基)噻唑-4(5H)-酮(化合物3a)的制备
制备方法同实施例一。以对氯苯乙酮代替实例一中的苯乙酮,得到淡黄色晶体状目标化合物。Yellow crystal,Yield 67%,mp:252-255℃.1H NMR(CDCl3,300MHz)δ:3.03-3.11(dd,J1=18.0Hz,J2=3.6Hz,1H),3.94(s,2H),4.07-4.16(dd,J1=18.0Hz,J2=11.4Hz,1H),6.65-6.70(dd,J1=11.4Hz,J2=3.3Hz,1H),7.00-7.03(d,J=7.2Hz,1H),7.37-7.47(m,3H),7.54-7.64(m,2H),7.79-7.82(d,J=8.1Hz,1H),7.86-7.89(d,J=8.4Hz,2H),7.96-7.99(d,J=8.1Hz,1H),8.15-8.18(d,J=8.1Hz,1H).MS(ESI):406.07(C22H17ClN3OS,[M+H]+).Anal.Calcd for C22H16ClN3OS:C,65.10;H,3.97;Cl,8.73;N,10.35;O,3.94;S,7.90.Found:C,64.92;H,3.97;N,10.35.
实施例四:2-(3-(4-溴苯基)-5-(萘-1-基)-4,5-二氢-1H-吡唑-1-基)噻唑-4(5H)-酮(化合物4a)的制备
制备方法同实施例一。以对溴苯乙酮代替实例一中的苯乙酮,得到淡黄色晶体状目标化合物。Yellow crystal,Yield 65%,mp:269-271℃.1H NMR(CDCl3,300MHz)δ:3.16-3.21(dd,J1=10.5Hz,J2=2.1Hz,1H),3.92(s,2H),4.00-4.05(dd,J1=10.5Hz,J2=6.9Hz,1H),6.19(s,1H),6.82-6.84(d,J=6.6Hz,1H),7.08-7.12(t,J=5.1Hz,2H),7.41-7.44(t,J=4.6Hz,1H),7.53-7.56(t,J=4.2Hz,1H),7.59-7.62(t,J=4.5Hz,1H),7.70-7.73(m,2H),7.79-7.81(d,J=4.8Hz,1H),7.90-7.92(d,J=4.8Hz,1H),8.01-8.03(d,J=5.1Hz,1H).MS(ESI):450.02(C22H17BrN3OS,[M+H]+).Anal.Calcd for C22H16BrN3OS:C,58.67;H,3.58;Br,17.74;N,9.33;O,3.55;S,7.12.Found:C,58.48;H,3.58;N,9.32.
实施例五:2-(3-(4-甲氧基苯基)-5-(萘-1-基)-4,5-二氢-1H-吡唑-1-基)噻唑-4(5H)-酮(化合物5a)的制备
制备方法同实施例一。以对甲氧基苯乙酮代替实例一中的苯乙酮,得到白色晶体状目标化合物。White crystal,Yield 69%,mp:224-225℃.1H NMR(CDCl3,300MHz)δ:3.15-3.19(dd,J1=10.4Hz,J2=2.1Hz,1H),3.83(s,3H),3.90(s,2H),3.98-4.02(dd,J1=10.5Hz,J2=6.9Hz,1H),6.78-6.80(d,J=4.9Hz,1H),6.89-6.91(d,J=5.4Hz,2H),7.21-7.23(d,J=4.3Hz,1H),7.40-7.43(t,J=4.5Hz,1H),7.52-7.55(t,J=4.2Hz,1H),7.58-7.61(t,J=4.2Hz,1H),7.63-7.66(d,J=5.4Hz,2H),7.78-7.80(d,J=4.9Hz,1H),7.90-7.92(d,J=4.8Hz,1H),8.02-8.04(d,J=5.1Hz,1H).MS(ESI):402.12(C23H20N3O2S,[M+H]+).Anal.Calcd for C23H19N3O2S:C,68.81;H,4.77;N,10.47;O,7.97;S,7.99.Found:C,68.63;H,4.77;N,10.46.
实施例六:2-(5-(萘-1-基)-3-(对甲苯基)-4,5-二氢-1H-吡唑-1-基)噻唑-4(5H)-酮(化合物6a)的制备
制备方法同实施例一。以对甲基苯乙酮代替实例一中的苯乙酮,得到白色晶体状目标化合物。White crystal,Yield 66%,mp:233-237℃.1H NMR(CDCl3,300MHz)δ:2.33(s,3H),3.01-3.08(dd,J1=18.0Hz,J2=3.6Hz,1H),3.89(s,2H),4.09-4.19(dd,J1=17.7Hz,J1=11.4Hz,1H),6.65-6.70(dd,J1=11.4Hz,J2=3.3Hz,1H),7.03-7.06(d,J=7.2Hz,1H),7.22-7.25(d,J=8.1Hz,1H),7.40-7.46(t,J=8.1Hz,1H),7.57-7.68(m,2H),7.75-7.78(d,J=8.1Hz,2H),7.81-7.84(d,J=8.1Hz,1H),7.98-8.01(d,J=7.8Hz,2H),8.17-8.20(d,J=8.4Hz,1H).MS(ESI):386.12(C23H20N3OS,[M+H]+).Anal.Calcd for C23H19N3OS:C,71.66;H,4.97;N,10.90;O,4.15;S,8.32.Found:C,71.52;H,4.96;N,10.89.
实施例七:2-(3-(3,4-二氯苯基)-5-(萘-1-基)-4,5-二氢-1H-吡唑-1-基)噻唑-4(5H)-酮(化合物7a)的制备
制备方法同实施例一。以3,4-二氯苯乙酮代替实例一中的苯乙酮,得到淡黄色晶体状目标化合物。Yellow crystal,Yield 61%,mp:260-264℃.1H NMR(CDCl3,300MHz)δ:3.16-3.25(dd,J1=17.7Hz,J2=3.6Hz,1H),3.95(s,2H),4.05-4.14(dd,J1=17.7Hz,J2=11.4Hz,1H),6.68-6.74(dd,J1=11.4Hz,J2=3.3Hz,1H),7.02-7.05(d,J=7.2Hz,1H),7.57-7.62(m,3H),7.65-7.70(m,2H),8.00-8.02(d,J=4.8Hz,1H),8.21-8.22(d,J=4.2Hz,1H),8.26(s,1H),8.35-8.37(d,J=5.1Hz,1H).MS(ESI):440.03(C22H16Cl2N3OS,[M+H]+).Anal.Calcd for C22H15Cl2N3OS:C,60.01;H,3.43;Cl,16.10;N,9.54;O,3.63;S,7.28.Found:C,59.88;H,3.43;N,9.54.
实施例八:2-(5-(萘-2-基)-3-苯基-4,5-二氢-1H-吡唑-1-基)噻唑-4(5H)-酮(化合物1b)的制备
制备方法同实施例一。以2-萘甲醛代替实例一中的1-萘甲醛,得到白色粉末状目标化合物。White powder,Yield 65%,mp:222-224℃.1H NMR(CDCl3,300MHz)δ:3.23-3.27(dd,J1=10.8Hz,J2=2.4Hz,1H),3.91(s,2H),3.99-4.04(dd,J1=10.8Hz,J2=6.9Hz,1H),6.08-6.12(dd,J1=6.9Hz,J2=2.4Hz,1H),7.29-7.31(dd,J1=5.1Hz,J2=0.9Hz,1H),7.46-7.52(m,5H),7.65(s,1H),7.87-7.92(m,5H).MS(ESI):372.11(C22H18N3OS,[M+H]+).Anal.Calcd for C22H17N3OS:C,71.14;H,4.61;N,11.31;O,4.31,S,8.63.Found:C,70.93;H,4.61;N,11.31.
实施例九:2-(3-(4-氟苯基)-5-(萘-2-基)-4,5-二氢-1H-吡唑-1-基)噻唑-4(5H)-酮(化合物2b)的制备
制备方法同实施例一。以对氟苯乙酮代替实例一中的苯乙酮并以2-萘甲醛代替实施例一中的1-萘甲醛,得到白色粉末状目标化合物。White powder,Yield 66%,mp:233-234℃.1H NMR(CDCl3,300MHz)δ:3.15-3.19(dd,J1=10.8Hz,J2=2.1Hz,1H),3.89-3.95(m,3H),6.04(m,1H),7.45-7.47(d,J=5.1Hz,2H),7.53-7.55(m,2H),7.90-7.96(m,4H),8.06(m,1H),8.12(s,1H),8.16-8.18(d,J=5.1Hz,1H).MS(ESI):390.10(C22H17FN3OS,[M+H]+).Anal.Calcd for C22H16FN3OS:C,67.85;H,4.14;F,4.88;N,10.79;O,4.11;S,8.23.Found:C,67.65;H,4.13;N,10.78.
实施例十:2-(3-(4-氯苯基)-5-(萘-2-基)-4,5-二氢-1H-吡唑-1-基)噻唑-4(5H)-酮(化合物3b)的制备
制备方法同实施例一。以对氯苯乙酮代替实例一中的苯乙酮并以2-萘甲醛代替实施例一中的1-萘甲醛,得到淡黄色粉末状目标化合物。Yellow powder,Yield 68%,mp:243-245℃.1H NMR(CDCl3,300MHz)δ:3.21-3.26(dd,J1=11.1Hz,J2=2.4Hz,1H),3.93(s,2H),3.96-4.02(dd,J1=11.1Hz,J2=6.9Hz,1H),6.08-6.11(dd,J1=6.9Hz,J2=2.1Hz,1H),7.29-7.30(d,J=4.5Hz,1H),7.45-7.50(m,3H),7.52-7.54(d,J=5.7Hz,1H),7.64(s,1H),7.86-7.94(m,5H).MS(ESI):406.07(C22H17ClN3OS,[M+H]+).Anal.Calcd for C22H16ClN3OS:C,65.10;H,3.97;Cl,8.73;N,10.35;O,3.94;S,7.90.Found:C,64.97;H,3.97;N,10.35.
实施例十一:2-(3-(4-溴苯基)-5-(萘-2-基)-4,5-二氢-1H-吡唑-1-基)噻唑-4(5H)-酮(化合物4b)的制备
制备方法同实施例一。以对溴苯乙酮代替实例一中的苯乙酮并以2-萘甲醛代替实施例一中的1-萘甲醛,得到淡黄色粉末状目标化合物。Yellow powder,Yield 64%,mp:273-275℃.1H NMR(CDCl3,300MHz)δ:3.00-3.05(dd,J1=11.9Hz,J2=3.3Hz,1H),3.92(s,2H),4.15-4.20(dd,J1=10.8Hz,J2=6.6Hz,1H),5.42(m,1H),7.17-7.19(d,J=5.1Hz,1H),7.25-7.36(m,4H),7.39-7.43(m,1H),7.48(m,1H),7.53-7.55(d,J=5.1Hz,1H),7.58-7.60(d,J=5.1Hz,1H),7.62-7.64(d,J=5.1Hz,1H),7.70-7.72(d,J=5.1Hz,1H).MS(ESI):450.02(C22H17BrN3OS,[M+H]+).Anal.Calcd for C22H16BrN3OS:C,58.67;H,3.58;Br,17.74;N,9.33;O,3.55;S,7.12.Found:C,58.49;H,3.58;N,9.32.
实施例十二:2-(3-(4-甲氧基苯基)-5-(萘-2-基)-4,5-二氢-1H-吡唑-1-基)噻唑-4(5H)-酮(化合物5b)的制备
制备方法同实施例一。以对甲氧基苯乙酮代替实例一中的苯乙酮并以2-萘甲醛代替实例一中的1-萘甲醛,得到白色粉末状目标化合物。Whitepowder,Yield 69%,mp:210-212℃.1H NMR(CDCl3,300MHz)δ:3.20-3.25(dd,J1=10.8Hz,J2=2.1Hz,1H),3.80(s,3H),3.89(s,2H),3.93-3.99(dd,J1=10.8Hz,J2=6.9Hz,1H),6.05-6.08(dd,J1=6.9Hz,J2=2.1Hz,1H),6.99-7.01(d,J=5.1Hz,2H),7.28-7.30(d,J=5.1Hz,1H),7.45-7.51(m,2H),7.62(s,1H),7.83-7.89(m,5H).MS(ESI):402.12(C23H20N3O2S,[M+H]+).Anal.Calcd for C23H19N3O2S:C,68.81;H,4.77;N,10.47;O,7.97;S,7.99.Found:C,68.63;H,4.76;N,10.46.
实施例十三:2-(5-(萘-2-基)-3-(对甲苯基)-4,5-二氢-1H-吡唑-1-基)噻唑-4(5H)-酮(化合物6b)的制备
制备方法同实施例一。以对甲基苯乙酮代替实例一中的苯乙酮并以2-萘甲醛代替实施例一中的1-萘甲醛,得到白色粉末状目标化合物。White powder,Yield 63%,mp:199-202℃.1H NMR(CDCl3,300MHz)δ:2.34(s,3H),3.20-3.23(dd,J1=10.8Hz,J2=2.4Hz,1H),3.89(s,2H),3.95-4.01(dd,J1=11.1Hz,J2=6.9Hz,1H),6.05-6.08(dd,J1=6.9Hz,J2=2.4Hz,1H),7.27-7.28(d,J=4.8Hz,2H),7.30(d,J=0.9Hz,1H),7.48-7.51(m,2H),7.62(s,1H),7.78-7.80(d,J=5.1Hz,2H),7.85-7.86(m,3H).MS(ESI):386.12(C23H20N3OS,[M+H]+).Anal.Calcd forC23H19N3OS:C,71.66;H,4.97;N,10.90;O,4.15;S,8.32.Found:C,71.45;H,4.96;N.10.89.
实施例十四:2-(3-(3,4-二氯苯基)-5-(萘-2-基)-4,5-二氢-1H-吡唑-1-基)噻唑-4(5H)-酮(化合物7b)的制备
制备方法同实施例一。以3,4-二氯苯乙酮代替实例一中的苯乙酮并以2-萘甲醛代替实施例一中的1-萘甲醛,得到淡黄色粉末状目标化合物。Yellow powder,Yield59%,mp:261-264℃.1H NMR(CDCl3,300MHz)δ:3.25-3.30(dd,J1=10.8Hz,J2=2.4Hz,1H),3.92(s,2H),3.95-4.01(dd,J1=11.1Hz,J2=7.2Hz,1H),6.08-6.11(dd,J1=6.9Hz,J2=2.1Hz,1H),7.28-7.30(d,J=4.2Hz,1H),7.48-7.52(m,2H),7.63(s,1H),7.71-7.73(d,J=5.1Hz,1H),7.81-7.83(dd,J1=5.1Hz,J2=1.2Hz,1H),7.86-7.88(m,2H),8.14-8.17(d,J=6.6Hz,2H).MS(ESI):440.03(C22H16Cl2N3OS,[M+H]+).Anal.Calcd for C22H15Cl2N3OS:C,60.01;H,3.43;Cl,16.10;N,9.54;O,3.63;S,7.28.Found:C,59.89;H,3.42;N,9.53.
本发明的优点是:本发明所述的衍生物具有独特的噻唑啉酮结构,被报道是许多酶抑制剂的特征结构,易被靶标识别和结合;首次将噻唑啉酮结构与萘环和吡唑啉结构进行合理拼接,强化了药效基团的比例,增大了运输和透膜的可能。
Claims (7)
2.根据权利要求1所述的含萘环和噻唑啉酮结构的吡唑啉类衍生物,其特征是所述衍生物由以下步骤制备:
步骤1、将取代基苯乙酮,萘甲醛溶于有机溶剂中,磁搅拌使混合均匀,缓慢滴入NaOH溶液,磁搅拌,常温反应2h,产物以固体析出。反应结束后抽滤,并以大量的蒸馏水和冷乙醇洗涤固体,干燥,重结晶;
步骤2、将步骤1中所得产物与硫代氨基脲,以有机溶剂加热溶解,加热搅拌反应10h,反应结束后,冷却,产物以固体形态析出,抽滤并以冷乙醇洗涤,干燥,重结晶;
步骤3、将步骤2中所得产物、溴乙酸乙酯与乙酸钠,以有机溶剂加热溶解,加热搅拌反应5h,反应结束后,冷却,产物以固体形态析出,抽滤并以冷乙醇洗涤,重结晶得到目标化合物。
3.根据权利要求1或2所述的含萘环和噻唑啉酮结构的吡唑啉类衍生物,其特征是步骤1中所述的取代苯乙酮与萘甲醛的投料摩尔比为1∶(1-1.1),最优投料摩尔比为1∶1.05,所述的有机溶剂为乙醇,所述的磁搅拌时间为10min,所述的萘甲醛可以分别为1-萘甲醛或2-萘甲醛,所述pH值为8-10,最优pH值为9.1,所述的反应温度为常温,所述的重结晶条件为采用体积比为10∶1的乙醇与丙酮混合液重结晶。
4.根据权利要求1或2所述的含萘环和噻唑啉酮结构的吡唑啉类衍生物,其特征是步骤2中所述的第一步产物与硫代氨基脲的投料摩尔比为1∶(1-1.1),最优投料摩尔比为1∶1.05,所述的有机溶剂为异丙醇或乙醇,所述的反应温度为75-85℃,最优反应温度为80℃,所述的冷却温度为5℃以下,所述的重结晶条件为采用体积比为10∶1的乙醇与丙酮混合液重结晶。
5.根据权利要求1或2所述的含萘环和噻唑啉酮结构的吡唑啉类衍生物,其特征是步骤3中所述的第二步产物与溴乙酸乙酯、乙酸钠的投料摩尔比为1∶(1-1.1)∶(1.0-1.8),最优投料摩尔比为1∶1∶1.5,所述的有机溶剂为异丙醇或乙醇,所述的反应温度为75-85℃,最优反应温度为80℃,所述的冷却温度为5℃以下,所述的重结晶条件为采用体积比为10∶1的乙醇与丙酮混合液重结晶。
6.一类含萘环和噻唑啉酮结构的吡唑啉类衍生物的制备方法,其特征是所述方法包括以下步骤:
步骤1、将取代基苯乙酮,萘甲醛溶于有机溶剂中,磁搅拌使混合均匀,缓慢滴入NaOH溶液,磁搅拌,常温反应2h,产物以固体析出。反应结束后抽滤,并以大量的蒸馏水和冷乙醇洗涤固体,干燥,重结晶;
步骤2、将步骤1中所得产物与硫代氨基脲,以有机溶剂加热溶解,加热搅拌反应10h,反应结束后,冷却,产物以固体形态析出,抽滤并以冷乙醇洗涤,干燥,重结晶;
步骤3、将步骤2中所得产物、溴乙酸乙酯与乙酸钠,以有机溶剂加热溶解,加热搅拌反应5h,反应结束后,冷却,产物以固体形态析出,抽滤并以冷乙醇洗涤,重结晶得到目标化合物。
7.根据权利要求6所述的含萘环和噻唑啉酮结构的吡唑啉类衍生物的制备方法,其特征是:
步骤1中所述的取代苯乙酮与萘甲醛的投料摩尔比为1∶(1-1.1),最优投料摩尔比为1∶1.05,所述的有机溶剂为乙醇,所述的磁搅拌时间为10min,所述的萘甲醛可以分别为1-萘甲醛或2-萘甲醛,所述pH值为8-10,最优pH值为9.1,所述的反应温度为常温,所述的重结晶条件为采用体积比为10∶1的乙醇与丙酮混合液重结晶;
步骤2中所述的第一步产物与硫代氨基脲的投料摩尔比为1∶(1-1.1),最优投料摩尔比为1∶1.05,所述的有机溶剂为异丙醇或乙醇,所述的反应温度为75-85℃,最优反应温度为80℃,所述的冷却温度为5℃以下,所述的重结晶条件为采用体积比为10∶1的乙醇与丙酮混合液重结晶;
步骤3中所述的第二步产物与溴乙酸乙酯、乙酸钠的投料摩尔比为1∶(1-1.1)∶(1.0-1.8),最优投料摩尔比为1∶1∶1.5,所述的有机溶剂为异丙醇或乙醇,所述的反应温度为75-85℃,最优反应温度为80℃,所述的冷却温度为5℃以下,所述的重结晶条件为采用体积比为10∶1的乙醇与丙酮混合液重结晶。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210390426.3A CN103724337A (zh) | 2012-10-15 | 2012-10-15 | 一类含萘环和噻唑啉酮结构的吡唑啉类衍生物及其制法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210390426.3A CN103724337A (zh) | 2012-10-15 | 2012-10-15 | 一类含萘环和噻唑啉酮结构的吡唑啉类衍生物及其制法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN103724337A true CN103724337A (zh) | 2014-04-16 |
Family
ID=50448666
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201210390426.3A Pending CN103724337A (zh) | 2012-10-15 | 2012-10-15 | 一类含萘环和噻唑啉酮结构的吡唑啉类衍生物及其制法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103724337A (zh) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060287319A1 (en) * | 2005-06-15 | 2006-12-21 | Shibo Jiang | Anti-viral compositions comprising heterocyclic substituted phenyl furans and related compounds |
CN101759695A (zh) * | 2009-12-30 | 2010-06-30 | 南京大学 | 一类含有吡唑环的噻唑类衍生物及其制法和用途 |
-
2012
- 2012-10-15 CN CN201210390426.3A patent/CN103724337A/zh active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060287319A1 (en) * | 2005-06-15 | 2006-12-21 | Shibo Jiang | Anti-viral compositions comprising heterocyclic substituted phenyl furans and related compounds |
CN101759695A (zh) * | 2009-12-30 | 2010-06-30 | 南京大学 | 一类含有吡唑环的噻唑类衍生物及其制法和用途 |
Non-Patent Citations (5)
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Gopi et al. | Imidazoles from nitroallylic acetates and α-bromonitroalkenes with amidines: Synthesis and trypanocidal activity studies | |
JP6732744B2 (ja) | ルテニウム触媒作用によるアゾベンゾール類からのビフェニルアミン類の製造方法 | |
Mady et al. | Microwave-assisted synthesis of novel pyrazole and pyrazolo [3, 4-d] pyridazine derivatives incorporating diaryl sulfone moiety as potential antimicrobial agents | |
KR102006246B1 (ko) | 3번 위치에 아릴기가 치환된 퀴녹살린온 유도체의 제조방법 | |
RU2497811C2 (ru) | Фенилимидазольные соединения | |
Zhang et al. | Copper (I)‐Catalyzed Intramolecular N‐N Coupling of Cyclopropyl O‐Acyl Ketoximes: Synthesis of Spiro‐fused Pyrazolin‐5‐ones | |
Khattab et al. | Different synthetic routes to 4-(1 H-benzo [d] imidazol-2-yl) aniline | |
CN104592144A (zh) | 制备噁唑衍生物的新方法 | |
CN103724337A (zh) | 一类含萘环和噻唑啉酮结构的吡唑啉类衍生物及其制法 | |
Ibrahim et al. | Synthesis and investigation of mass spectra of some novel benzimidazole derivatives | |
Saha et al. | K2S2O8 mediated metal free oxidative coupling of alcohols with 1, 2-diaminobenzenes for synthesis of benzimidazoles, photophysical and DFT studies | |
CN103664783A (zh) | 一类含萘环和吡唑啉结构的硫脲类衍生物及其制法 | |
CN103374020B (zh) | 一类含萘环的噻唑[4,5-b]并喹喔啉类衍生物及其制法 | |
CN103304560A (zh) | 一类含吡唑啉与噻吩(或呋喃)结构的噻唑啉酮类衍生物及其制法与应用 | |
CN109879865B (zh) | 一种2-芳基-5-(2-喹啉基)-1,3,4-噁二唑类化合物的制备方法 | |
CN103450091A (zh) | 一类咪唑类衍生物及其制备方法与用途 | |
CN102731404A (zh) | 一种双吡唑环类化合物及其衍生物、制备方法及其应用 | |
CN1233631C (zh) | 取代苯基吡唑类除草剂 | |
CN103664784A (zh) | 一类含萘环的三芳基吡唑啉类衍生物及其制法 | |
CN106588909A (zh) | 一种喹啉类衍生物的制备及其在抗炎中的应用 | |
CN104557725A (zh) | 一种一锅法合成1,2-二芳基苯并咪唑及其衍生物的方法 | |
Gülbenek et al. | Microwave-mediated approach to highly substituted nitropyrimidines via double Mannich reactions and their biological properties | |
SR Murty et al. | An efficient nonconventional glycerol-based solid acid catalyzed synthesis and biological evaluation of phosphonate conjugates of 1, 2, 4-triazole thiones | |
CN103724338A (zh) | 一类含萘环和吡唑啉结构的噻唑类衍生物及其制法 | |
CN103304584B (zh) | 一类2-腙-噻唑并[4,5-b]喹喔啉类化合物及其制法与用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C12 | Rejection of a patent application after its publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20140416 |